Intermediate for Carfilzomib. Carfilzomib (trade name: Kyprolis) is an anti-cancer drug acting as a selective proteasome inhibitor. Carfilzomib has been approved by the U.S Food and Drug Administration on July 20, 2012.
Product Name: (4-Morpholinyl)acetic acid
CAS Number: 3235-69-6
Molecular Weight:  145.1578
Molecular Formula:  C6H11NO3
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.